Douglas A Mata, Jessica K Lee, Vignesh Shanmugam, Chelsea B Marcus, Alexa B Schrock, Erik A Williams, Lauren L Ritterhouse, Richard A Hickman, Tyler Janovitz, Nimesh R Patel, Benjamin R Kroger, Jeffrey S Ross, Kamran M Mirza, Geoffrey R Oxnard, Jo-Anne Vergilio, Julia A Elvin, Jamal K Benhamida, Brennan Decker, Mina L Xu
AIMS: Liquid biopsy (LBx)-based next-generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue-based NGS is infeasible. METHODS AND RESULTS: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non-Hodgkin lymphoma (NHL), 43 plasma-cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B-cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML)...
February 29, 2024: Histopathology